Researchers Increased siRNA Concentration for Home Therapy
A new membrane-charging and vibration technique enables the concentrations required for at-home delivery of siRNA treatments.
Updated on Sept. 25, 2026 in Chemistry
Live Poll
Should medical researchers prioritize developing drug manufacturing methods that enable at-home patient self-administration?
University of Pennsylvania researchers have demonstrated a method to reach siRNA concentrations of 230 mg/mL, surpassing the 200 mg/mL threshold needed for at-home administration. The results, published in the Journal of Membrane Science, represent a move toward more flexible delivery options for patients.
Why it matters
High levels of membrane fouling previously prevented the concentration of siRNA solutions to the levels required for self-administered therapeutic use. This approach enables the production of stable, high-concentration formulas, potentially expanding the clinical utility of current siRNA treatments.
The researchers achieved 230 mg/mL using 10 kDa cellulose membranes modified with a fixed negative charge to reduce fouling through electrostatic repulsion, combined with 22 Hz of oscillatory vibration. This is a significant increase over the 180 mg/mL achieved with negative charging alone.
The players
University of Pennsylvania
A research university recognized for advanced work in biotechnology, membrane science, and pharmaceutical engineering.
Eli Lilly
A global pharmaceutical firm focused on the development of therapeutic treatments and the sponsorship of advanced biochemical research.
The details
The team utilized a base chemistry reaction to introduce a negative charge on the membrane surface, which pushes away the molecules that typically clog filters. To further improve throughput, they integrated a pressurized air piston that applies oscillatory vibration—rapid, repetitive physical movement—along a single axis to the filtration unit. By preventing the accumulation of material on the filter, the system maintains consistent flow rates even as the siRNA reaches higher therapeutic densities.
Timeline
September 25, 2026: Findings were presented at the BioProcess International 2026 conference in Boston.
The Tech Race
This development addresses the critical threshold for at-home siRNA administration, a major focus for pharmaceutical manufacturers aiming to move beyond clinical settings. It marks a departure from standard filtration methods that have historically struggled to achieve necessary dosage densities without excessive membrane fouling.
This research enables the future development of higher-concentration siRNA therapeutics that patients could eventually self-administer at home. While the technology is currently in the research stage, successful implementation in manufacturing workflows will be required before these drugs reach the clinic.
The takeaway
The ability to hit the 200 mg/mL threshold is the primary technical hurdle for transitioning siRNA treatments out of clinical settings. Readers should watch for future manufacturing trials that scale this oscillatory filtration method into full-scale drug production pipelines.
What happens next
The research team will present further data on their methodology at the BioProcess International 2026 event held in Boston in September 2026.
Further reading
For more on the latest research in molecular processing, see our Chemistry section.
Source note: This article includes information reported by BioXconomy.
Live Poll
Should medical researchers prioritize developing drug manufacturing methods that enable at-home patient self-administration?
